Chordia Therapeutics,Inc (190A) Cash flow
Market cap
¥10.8B
P/E ratio
-5.4x
Chordia Therapeutics discovers and develops innovative small-molecule cancer drugs that target RNA regulatory stress in cancer cells for pharmaceutical partners.
| 2022/08 | 2023/08 | 2024/08 | 2025/08 | |
| Depreciation & amortization | 3 | 6 | 4 | 3 |
| Cash from operations | -1,704 | 544 | -1,937 | -1,837 |
| Capital expenditures | -9 | -0 | -1 | -5 |
| Cash from investing | -15 | 0 | -11 | -5 |
| Cash from financing | 3,976 | - | 1,479 | 62 |